Curated News
By: NewsRamp Editorial Staff
July 28, 2025

Phlow Corp Secures $37M in Series C Funding to Combat Drug Shortages

Reddit Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Phlow Corp's $37 million Series C funding, led by Align Private Capital, enhances its capacity to secure a competitive edge in the pharmaceutical supply chain and API manufacturing.
  • Phlow Corp has raised over $93 million in private capital and secured $600 million in government contracts to methodically expand its API production and combat drug shortages.
  • Phlow Corp's initiatives, including the Children’s Hospital Coalition, aim to make the world better by addressing pediatric drug shortages and ensuring essential medicines reach those in need.
  • Phlow Corp, with its innovative approach, has shipped over 1.6 million vials of essential medicines, showcasing its commitment to revolutionizing the pharmaceutical supply chain.

Impact - Why it Matters

This news is crucial as it highlights Phlow Corp's efforts to address and mitigate the chronic shortages of essential medicines in the U.S., including those for pediatric care. By securing significant funding and forming strategic partnerships, Phlow is enhancing the resilience of the pharmaceutical supply chain, ensuring the availability of critical medications for Americans, especially in times of health crises. Their work not only supports the general public but also aids the U.S. military and its allies in preparing for chemical and biological threats, showcasing a comprehensive approach to national healthcare security.

Summary

Phlow Corp, a Richmond, Va.-based contract development and manufacturing organization (CDMO), has successfully closed a $37 million Series C funding round, led by Align Private Capital, a woman-owned investment firm. This funding round marks a significant milestone for Phlow, which has now raised over $93 million in private capital, in addition to more than $600 million in government contracts. The company, under the leadership of CEO Eric S. Edwards, is focused on stabilizing the U.S. pharmaceutical supply chain and addressing chronic shortages of essential medicines. Phlow's recent achievements include the opening of two cGMP manufacturing facilities and a partnership with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop medical countermeasures. Furthermore, Phlow's Children's Hospital Coalition has already distributed over 1.6 million vials of essential medicines to children's hospitals nationwide.

Source Statement

This curated news summary relied on content disributed by citybiz. Read the original source here, Phlow Corp Secures $37M in Series C Funding to Combat Drug Shortages

blockchain registration record for this content.